119.07
1.40%
-1.69
After Hours:
119.00
-0.07
-0.06%
Overview
News
Price History
Option Chain
Why NVO Down?
Discussions
Forecast
Stock Split
Dividend History
Novo Nordisk Adr stock is traded at $119.07, with a volume of 6.84M.
It is down -1.40% in the last 24 hours and down -14.44% over the past month.
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
See More
Previous Close:
$120.76
Open:
$117.59
24h Volume:
6.84M
Relative Volume:
1.74
Market Cap:
$527.33B
Revenue:
$37.42B
Net Income/Loss:
$13.05B
P/E Ratio:
49.45
EPS:
2.4077
Net Cash Flow:
$9.51B
1W Performance:
-3.74%
1M Performance:
-14.44%
6M Performance:
-7.27%
1Y Performance:
+30.93%
Novo Nordisk Adr Stock (NVO) Company Profile
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-30-24 | Initiated | Goldman | Buy |
Apr-12-24 | Initiated | BMO Capital Markets | Outperform |
Jan-23-24 | Initiated | Morgan Stanley | Overweight |
Jan-16-24 | Resumed | UBS | Neutral |
Dec-01-23 | Initiated | Cantor Fitzgerald | Overweight |
Oct-02-23 | Initiated | Argus | Buy |
Jul-14-23 | Initiated | HSBC Securities | Buy |
Jul-15-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jun-28-22 | Downgrade | UBS | Neutral → Sell |
Jun-27-22 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
Jun-07-22 | Upgrade | JP Morgan | Neutral → Overweight |
May-31-22 | Upgrade | Guggenheim | Neutral → Buy |
Apr-25-22 | Upgrade | Cowen | Market Perform → Outperform |
Apr-12-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
Mar-16-22 | Upgrade | Deutsche Bank | Hold → Buy |
Jan-25-22 | Downgrade | Liberum | Hold → Sell |
Dec-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
Dec-17-21 | Downgrade | Deutsche Bank | Buy → Hold |
Jan-20-21 | Downgrade | Credit Suisse | Outperform → Neutral |
Jan-15-21 | Initiated | Deutsche Bank | Buy |
Sep-29-20 | Initiated | Berenberg | Hold |
Jul-06-20 | Downgrade | BofA Securities | Buy → Neutral |
May-11-20 | Downgrade | UBS | Buy → Neutral |
May-04-20 | Initiated | Cowen | Market Perform |
Mar-16-20 | Upgrade | BofA/Merrill | Neutral → Buy |
Jan-03-20 | Downgrade | Guggenheim | Buy → Neutral |
Nov-18-19 | Upgrade | Barclays | Equal Weight → Overweight |
Sep-17-19 | Upgrade | Citigroup | Neutral → Buy |
Aug-30-19 | Downgrade | Jefferies | Hold → Underperform |
Jun-20-19 | Downgrade | Deutsche Bank | Buy → Hold |
Jun-11-19 | Upgrade | Barclays | Underweight → Equal Weight |
Apr-29-19 | Upgrade | Credit Suisse | Neutral → Outperform |
Jan-29-19 | Initiated | Exane BNP Paribas | Outperform |
Dec-11-18 | Resumed | Jefferies | Hold |
Oct-09-18 | Initiated | Guggenheim | Buy |
Dec-29-17 | Upgrade | JP Morgan | Underweight → Neutral |
Dec-06-17 | Upgrade | BofA/Merrill | Neutral → Buy |
Dec-01-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Sep-25-17 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
Sep-06-17 | Upgrade | BofA/Merrill | Underperform → Neutral |
View All
Novo Nordisk Adr Stock (NVO) Latest News
Novo Nordisk ADR (NVO) Stock: A Year of Decreases and Increases - The InvestChronicle
3 Stocks That Could Rise on European Bank Interest Rate Cuts - Benzinga
Novo Nordisk Slips On Analyst Warning Of Weaker Wegovy Sales - Investor's Business Daily
Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy? - The Motley Fool
Prediction: Eli Lilly Will Dominate the Billion-Dollar Weight Loss Drug Market for This Key Reason - The Motley Fool
Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development - Benzinga
Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why. - The Motley Fool
Eli Lilly Stock: Is LLY Stock A Buy After Snagging Approval For A New Eczema Drug? - Investor's Business Daily
Analysts review Novo Nordisk ADR’s rating - Knox Daily
DexCom Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool
EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen' - Benzinga
Why This Stock Could Be the Nvidia of Healthcare - The Motley Fool
Wall Street Analyst Initiated Novo Nordisk ADR [NVO]. What else is Wall St. saying - The DBT News
Novo Nordisk A/S ADR (NVO-N) QuotePress Release - The Globe and Mail
Balance Sheet Insights: Novo Nordisk ADR (NVO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk? - Morningstar
Novo Nordisk ADR (NVO) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
European Equities Traded in the US as American Depositary Receipts Decrease Friday - MSN
Novo Nordisk A/S (NVO) Stock Price, News, Quote & History - Yahoo Finance
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today - The Motley Fool
Novo Dives — And Corbus Crashes — On Psychiatric Side Effects Of Weight-Loss Drug - Investor's Business Daily
Novo Nordisk Stock Declines After Headline Results From Mid-Stage Study Of Monlunabant In Obese Patients - Benzinga
European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure - Benzinga
Novo Nordisk ADR (NVO)’s Day in Review: Closing at 132.06, Up by 0.05 - The Dwinnex
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks - The Motley Fool
Novo Nordisk Inks $600M Genetic Medicines Pact With Canadian Firm To Target Cardiometabolic Indications - Benzinga
Understanding the Risks of Investing in Novo Nordisk ADR (NVO) - Knox Daily
Novo Nordisk ADR Inc. (NVO) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments - The Motley Fool
Novo Nordisk ADR Sees Its Composite Rating Rise To 96 - Investor's Business Daily
Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now. - The Motley Fool
Should You Invest in This Under-the-Radar Weight Loss Stock? - The Motley Fool
2 Unstoppable Healthcare Stocks to Buy Right Now for Less Than $200 - The Motley Fool
Why Investors Plowed Into Viking Therapeutics Stock Today - The Motley Fool
NVO: With Obesity Drug Demand Surging, Is Novo Nordisk a Buy? - StockNews.com
Market Analysts see Novo Nordisk ADR [NVO] gaining to $156. Time to buy? - The DBT News
Why Roche Holdings Stock Withered on Wednesday - The Motley Fool
Novo Jumps After Weight-Loss Pill Tops Wegovy; Lilly, Viking Shares Rise - Investor's Business Daily
Can Novo Nordisk ADR Bounce Back? 52-Week Performance and Analyst Predictions - The InvestChronicle
Ozempic Maker Novo Nordisk Touts Encouraging Data From New Obesity Pill Showing Double Weight Loss Compared To Wegovy - Benzinga
Is Hims & Hers Health the Next Teladoc? - The Motley Fool
This Unstoppable Stock Has Gained 100,203% Over The Last 50 Years, Creating Many Millionaires in the Process. Here Are 3 Reasons I Think It Will Continue to Create Generational Wealth. - The Motley Fool
Billionaires Are Buying Viking Therapeutics Stock Left and Right. Should You Follow Their Lead? - The Motley Fool
Novo Nordisk ADR [NVO] Stock trading around $130.89 per share: What’s Next? - The DBT News
This Big Move by Eli Lilly May Solve the Weight Loss Drug Market's Biggest Problem - The Motley Fool
Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts - Benzinga
Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern - Benzinga
Battle Over Compounded Weight-Loss Medications - Benzinga
Eli Lilly Just Made Zepbound Even More Appealing. Here's What Smart Investors Need to Know. - The Motley Fool
Down a Monstrous 90% This Year, Is There Any Hope Left for Ginkgo Bioworks Investors? - The Motley Fool
BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race - Benzinga
Novo Nordisk Adr Stock (NVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):